Skip to main content
SpringerLink
Log in

Antipsychotic Agents

  • Chapter
  • First Online:
Chemotherapy in Psychiatry

  • 1552 Accesses

Abstract

The start of the era of modern psychopharmacology can be dated from 1949, with the introduction of lithium carbonate in Melbourne, Australia, as a selective and effective antimanic agent. However, the earliest antipsychotic drugs appeared soon after that, and exerted immediate and truly revolutionary changes in the care of the severely mentally ill. The first modern antipsychotics were the phenothiazines, starting with the discovery of antimanic and antipsychotic properties of chlorpromazine in Paris in 1952.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2008;13:479–95.

    PubMed  CAS  Google Scholar 

  2. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiary. 2001;179:290–9.

    CAS  Google Scholar 

  3. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States. Pharmacoepidemiol Drug Safety. 2011;20:177–84.

    CAS  Google Scholar 

  4. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Safety. 2010;5:97–104.

    CAS  Google Scholar 

  5. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993;329:162–7.

    PubMed  CAS  Google Scholar 

  6. American Psychiatric Association. Diagnostic and statistical manual. 4th ed., text revision. Washington, DC: American Psychiatric Press; 2000.

    Google Scholar 

  7. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464–70.

    PubMed  CAS  Google Scholar 

  8. Arinami T, Inada T. [Genome-wide association analyses for neuroleptic-induced tardive dyskinesia (Japanese)]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2011;31:155–62.

    PubMed  CAS  Google Scholar 

  9. Avital A, Gross-Isseroff R, Stryjer R, Hermesh H, Weizman A, Shiloh R. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. Eur Neuropsychopharmacol. 2009;19:476–82.

    PubMed  CAS  Google Scholar 

  10. Azoulay L, Yin H, Renoux C, Suissa S. The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat. 2011;129:541–8.

    PubMed  CAS  Google Scholar 

  11. Baldessarini RJ. Chemotherapy in psychiatry. 2nd ed. Cambridge, MA: Harvard University Press; 1985.

    Google Scholar 

  12. Baldessarini RJ. Dopamine receptors and clinical medicine. In: Neve KA, Neve RL, editors. The dopamine receptors. Totowa, NJ: Humana; 1997. p. 457–98.

    Google Scholar 

  13. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988;45:79–91.

    PubMed  CAS  Google Scholar 

  14. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do antiadrenergic actions contribute to the atypical properties of clozapine? Br J. Psychiatry. 1992;160:12–6.

    Google Scholar 

  15. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med. 1991;324:746–54.

    PubMed  CAS  Google Scholar 

  16. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Ther. 1996;3:492–6.

    PubMed  Google Scholar 

  17. Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996;3:301–25.

    PubMed  CAS  Google Scholar 

  18. Baldessarini RJ, Tarazi FI. Pharmacotherapy of mood disorders, anxiety, psychosis and mania (Chaps. 17 and 18). In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York, NY: McGraw Hill; 2005. p. 429–500.

    Google Scholar 

  19. Baldessarini RJ, Tarsy D. Pathophysiologic basis of neurologic side-effects of antipsychotic drugs. Ann Rev Neurobiol. 1980;3:23–41.

    CAS  Google Scholar 

  20. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Discontinuation rate vs. recurrence risk following long-term antidepressant treatment in major depressive disorder patients. Am J Psychiatry. 2010;167:934–41.

    PubMed  Google Scholar 

  21. Ban TA. Clinical pharmacology of the phenothiazines. Appl Ther. 1966;8:423–7.

    PubMed  CAS  Google Scholar 

  22. Beaulieu JM, Gainetdinov RR. Physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182–217.

    PubMed  CAS  Google Scholar 

  23. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol. 2011;165:209–15.

    PubMed  CAS  Google Scholar 

  24. Bhuvaneswar C, Alpert J, Harsh V, Baldessarini RJ. Adverse endocrine and metabolic effects of psychotropic drugs. CNS Drugs. 2009;23:1003–21.

    PubMed  CAS  Google Scholar 

  25. Bleuler M, Stoll WA. Clinical use of reserpine in psychiatry: comparison with chlorpromazine. Ann N Y Acad Sci. 1955;61:167–73.

    PubMed  CAS  Google Scholar 

  26. Blom MT, Bardai A, van Munster BC, Nieuwland MI, de Jong H, van Hoeijen DA, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6:e23728.

    PubMed  CAS  Google Scholar 

  27. Bloomfield K, Macdonald L, Finucane G, Snow B, Roxburgh R. The use of antipsychotic medications in patients with Parkinson’s Disease at Auckland City Hospital. Intern Med J. [Epub ahead of print: 6 April 2011].

    Google Scholar 

  28. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29:64–73.

    PubMed  CAS  Google Scholar 

  29. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: update on epidemiology and postulated mechanisms. Intern Med J. 2008;38:602–6.

    PubMed  CAS  Google Scholar 

  30. Bushe CJ, Bradley A, Pendlebury J. Review of hyperprolactinaemia and severe mental illness. Ann Clin Biochem. 2010;47:292–300.

    PubMed  Google Scholar 

  31. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17:363–84.

    PubMed  CAS  Google Scholar 

  32. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry. 1999;46:1388–95.

    PubMed  CAS  Google Scholar 

  33. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175–82.

    PubMed  Google Scholar 

  34. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006;67:107–13.

    PubMed  CAS  Google Scholar 

  35. Centorrino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry. 2008;49:65–9.

    PubMed  Google Scholar 

  36. Centorrino F, Price BH, Tuttle M, Bahk WM, Hennen J, Albert MJ, Baldessarini RJ. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry. 2002;159:109–15.

    PubMed  Google Scholar 

  37. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol. 2010;25:179–86.

    PubMed  Google Scholar 

  38. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (Lond). 2006;30:1011–6.

    CAS  Google Scholar 

  39. Chahine LM, Acar D, Chemali Z. The elderly safety imperative and antipsychotic usage. Harv Rev Psychiatry. 2010;18:158–72.

    PubMed  Google Scholar 

  40. Chiang YL, Klainin-Yobas P, Ignacio J, Chng CM. Impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nurs. 2011;20:2172–82.

    PubMed  Google Scholar 

  41. Christodoulou C, Kalaitzi C. Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. J Psychopharmacol. 2005;19:307–11.

    PubMed  Google Scholar 

  42. Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009;9:55–71.

    PubMed  CAS  Google Scholar 

  43. Clement-Cormier YC, Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci USA. 1974;71:1113–7.

    PubMed  CAS  Google Scholar 

  44. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl). 1988;108:338–44.

    Google Scholar 

  45. Cooper HM, Hedges LV, Valentine J, editors. Handbook of research synthesis and meta-analysis. 2nd ed. New York, NY: Russell Sage; 2009.

    Google Scholar 

  46. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: systematic review of one-year studies. Am J Psychiatry. 2004;161:414–25.

    PubMed  Google Scholar 

  47. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16–22.

    PubMed  CAS  Google Scholar 

  48. Cure S, Rathbone J, Carpenter S. Droperidol for acute psychosis. Cochrane Database Syst Rev 2004;4:CD002830.

    Google Scholar 

  49. Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord. 2004;78:201–8.

    PubMed  CAS  Google Scholar 

  50. Cuyun-Carter GB, Milton DR, Ascher-Svanum H, Faries DE. Sustained favorable long-term outcome in the treatment of schizophrenia: 3-year prospective observational study. BMC Psychiatry. 2011;11:143.

    PubMed  Google Scholar 

  51. Dando S, Tohen M. Olanzapine: relapse prevention following mania. J Psychopharmacol. 2006;20 (Suppl 2):31–8.

    PubMed  CAS  Google Scholar 

  52. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- vs. second-generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007;191:14–22.

    PubMed  CAS  Google Scholar 

  53. Daya RP, Tan ML, Sookram CD, Skoblenick K, Mishra RK. Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioral and biochemical changes. Brain Res. 2011;1412:28–36.

    PubMed  CAS  Google Scholar 

  54. De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, Souery D, Claes S. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26:603–17.

    Google Scholar 

  55. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160:303–9.

    PubMed  Google Scholar 

  56. Ducomb L, Baldessarini RJ. Timing and risk of bone marrow depression by psychotropic drugs. Am J Psychiatry. 1977;134:1294–5.

    PubMed  CAS  Google Scholar 

  57. Duncan EJ, Adler LA, Stephanides M, Sanfilipo M, Angrist B. Akathisia and exacerbation of psychopathology: preliminary report. Clin Neuropharmacol. 2000;23:169–73.

    PubMed  CAS  Google Scholar 

  58. Eapen V, John G. Weight-gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go? Australas Psychiatry. 2011;19:232–5.

    PubMed  Google Scholar 

  59. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006;32:234–7.

    PubMed  Google Scholar 

  60. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168:702–8.

    PubMed  Google Scholar 

  61. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. METEOR study: frequency of metabolic disorders in patients with schizophrenia: focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011;26:291–302.

    PubMed  Google Scholar 

  62. FDA (US Food and Drug Administration). Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and pro-arrhythmic potential for non-antiarrhythmic drugs; 2005. http://www.fda.gov/6922fnl.pdf.

  63. Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky RB. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl). 2000;149:1–5.

    CAS  Google Scholar 

  64. Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognized life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206:e31–6.

    PubMed  CAS  Google Scholar 

  65. Frankenburg F, Baldessarini RJ. Neurosyphilis, malaria, and discovery of antipsychotic agents. Harv Rev Psychiatry. 2008;16:299–307.

    PubMed  Google Scholar 

  66. Froimowitz M, Cody V. Incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists. Drug Des Discov. 1997;15:63–81.

    PubMed  CAS  Google Scholar 

  67. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;1:9–13.

    Google Scholar 

  68. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. Relapse prevention in first-episode schizophrenia: maintenance vs. intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011;72:205–18.

    PubMed  Google Scholar 

  69. Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses. 2011;5:75–9.

    PubMed  Google Scholar 

  70. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic agents: a critical overview. Can Med Assoc J. 2005;172:1703–11.

    Google Scholar 

  71. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686–93.

    PubMed  Google Scholar 

  72. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf. 1992;7 (Suppl 1):17–25.

    PubMed  Google Scholar 

  73. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775–86.

    PubMed  Google Scholar 

  74. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010;25:1780–90.

    PubMed  Google Scholar 

  75. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692–9.

    PubMed  Google Scholar 

  76. Glass GV. Meta-analysis at 25. 2000. http://www.gvglass.info/papers/meta25.html.

  77. Glass GV, McGaw B, Smith ML. Meta-analysis in social research. Beverly Hills, CA: Sage; 1981.

    Google Scholar 

  78. Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2011;72:e13.

    PubMed  Google Scholar 

  79. Goldberg TE, Gomar JJ. Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry. 2009;166:631–4.

    PubMed  Google Scholar 

  80. Goldman JG, Vaughan CL, Goetz CG. Update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother. 2011;12:2009–24.

    PubMed  Google Scholar 

  81. Grande I, Pons A, Baeza I, Torras A, Bernardo M. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol. [Epub ahead of print, 9 Aug 2011].

    Google Scholar 

  82. Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009;29:65–8.

    PubMed  CAS  Google Scholar 

  83. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, Deroos F, Francis A, et al. International consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72:1222–8.

    PubMed  Google Scholar 

  84. Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 19932003. Drug Saf. 2007;30:47–57.

    PubMed  CAS  Google Scholar 

  85. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23:15–26.

    PubMed  Google Scholar 

  86. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux CM, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151: 1409–16.

    PubMed  CAS  Google Scholar 

  87. Herceg M, Muzinić L, Jukić V. Can we prevent blood dyscrasia (leucopenia, thrombocytopenia) and epileptic seizures induced by clozapine. Psychiatr Danub. 2010;22:85–9.

    PubMed  Google Scholar 

  88. Hollister LE. Clinical use of psychotherapeutic drugs: current status. Clin Pharmacol Ther. 1969;10:170–98.

    PubMed  CAS  Google Scholar 

  89. Gatyas G. IMS Health Reports U.S. prescription sales. Norwalk, CT: IMS Health; 2010. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid.

  90. Gitlin MJ, Midha KK, Fogelson D, Nuechterlein K. Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol. 1988;8:53–6.

    PubMed  CAS  Google Scholar 

  91. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185–94.

    PubMed  Google Scholar 

  92. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother. 2008;42:841–6.

    PubMed  CAS  Google Scholar 

  93. Howland RH. Drug therapies for tardive dyskinesia. J Psychosoc Nurs Ment Health Serv. 2011;49:13–20.

    Google Scholar 

  94. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011;45:830–7.

    PubMed  Google Scholar 

  95. Janssen PA. Evolution of the butyrophenones, haloperidol and trifluperidol, from meperidine-like 4-phenylpiperidines. Int Rev Neurobiol. 1965;8:221–63.

    PubMed  CAS  Google Scholar 

  96. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7:70–6.

    PubMed  CAS  Google Scholar 

  97. Jin H, Meyer J, Mudaliar S, Henry R, Khandrika S, Glorioso DK, et al. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. J Clin Psychiatry. 2010;71:1273–8.

    PubMed  Google Scholar 

  98. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.

    PubMed  CAS  Google Scholar 

  99. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122–7.

    PubMed  Google Scholar 

  100. Kamphuis H, Arends J, Timmerman L, van Marle J, Kappert J. [Myocarditis and cardiomyopathy: underestimated complications resulting from clozapine therapy (Dutch)]. Tijdschr Psychiatr. 2010;52:223–33.

    PubMed  CAS  Google Scholar 

  101. Kane JM. Antipsychotic drug side effects: relationship to dose. J Clin Psychiatry. 1985;46:16–21.

    PubMed  CAS  Google Scholar 

  102. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov III A, Assunção-Talbott S. Akathisia: updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70:627–43.

    PubMed  CAS  Google Scholar 

  103. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 1988;45:789–96.

    PubMed  CAS  Google Scholar 

  104. Kane JM, Stroup TS, Marder SR. Schizophrenia: pharmacological treatment (Chap. 12.12). In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins; 2009. p. 1546–55.

    Google Scholar 

  105. Karagianis J, Rosenbluth M, Tohen M, Ascher-Svanum H, Treuer T, de Lima MS, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin. 2007;23:2551–77.

    PubMed  Google Scholar 

  106. Karlsson P, Smith L, Farde L, Härnryd C, Sedvall G, Wiesel FA. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl). 1995;121:309–16.

    CAS  Google Scholar 

  107. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277:93–6.

    PubMed  CAS  Google Scholar 

  108. Kelleher JP, Centorrino F, Baldessarini RJ. New formulations and new atypical antipsychotics: potential therapeutic advantages. CNS Drugs. 2002;16:249–61.

    PubMed  CAS  Google Scholar 

  109. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009;35:347–61.

    PubMed  Google Scholar 

  110. Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat ⁄ harm help inform clinical decisions? Acta Psychiatr Scand. 2011;123:175–89.

    PubMed  CAS  Google Scholar 

  111. Kim HM, Chiang C, Kales HC. After the black box warning: predictors of psychotropic treatment choices for older patients with dementia. Psychiatr Serv. 2011;62:1207–14.

    PubMed  Google Scholar 

  112. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. [Epub ahead of print 29 Nov 2011].

    Google Scholar 

  113. Kline NS. Uses of reserpine, the newer phenothiazines, and iproniazid. Res Publ Assoc Res Nerv Ment Dis. 1959;37:218–44.

    PubMed  CAS  Google Scholar 

  114. Knegtering H, Oolders H, Ruijsink MA, van der Moolen AE. [Depot antipsychotics in the year 2011 (Dutch)]. Tijdschr Psychiatr. 2011;53:95–105.

    PubMed  CAS  Google Scholar 

  115. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;8:CD008121.

    Google Scholar 

  116. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 2000;157:987–93.

    PubMed  CAS  Google Scholar 

  117. Krebs MO. [Development of antipsychotic drug: new directions (French)]. Therapie. 2008;63:257–62.

    PubMed  Google Scholar 

  118. Kulkarni SK, Ninan I. Dopamine D4 receptors and development of newer antipsychotic drugs. Fundam Clin Pharmacol. 2000;14:529–39.

    PubMed  CAS  Google Scholar 

  119. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22:293–9.

    PubMed  Google Scholar 

  120. Kurzban S, Davis L, Brekke JS. Vocational, social, and cognitive rehabilitation for individuals diagnosed with schizophrenia: a review of recent research and trends. Curr Psychiatry Rep. 2010;12:345–55.

    PubMed  Google Scholar 

  121. Lako IM, Taxis K, Bruggeman R, Knegtering H, Burger H, Wiersma D, Slooff CJ. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur Psychiatry. 2012;27:240–4.

    Google Scholar 

  122. Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol. 2011;98:231–64.

    PubMed  CAS  Google Scholar 

  123. Lehmann HE, Hanrahan GE. Chlorpromazine, a new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry. 1954;71:227–37.

    PubMed  CAS  Google Scholar 

  124. Leong GB, Silva JA. Neuroleptic-induced akathisia and violence: a review. J Forensic Sci. 2003;48:187–9.

    PubMed  Google Scholar 

  125. Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry. 1979;136:1061–4.

    PubMed  CAS  Google Scholar 

  126. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry. 2002;159:1534–40.

    PubMed  Google Scholar 

  127. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17:242–66.

    PubMed  CAS  Google Scholar 

  128. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? Meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429–47.

    PubMed  CAS  Google Scholar 

  129. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: meta-analysis. Lancet. 2009;373:31–41.

    PubMed  CAS  Google Scholar 

  130. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia—critical systematic review and meta-analysis of randomized long-term trials. Schizophr Res. 2011;127:83–92.

    PubMed  Google Scholar 

  131. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39:1591–602.

    PubMed  CAS  Google Scholar 

  132. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. Meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152–63.

    PubMed  Google Scholar 

  133. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011;45:525–31.

    PubMed  CAS  Google Scholar 

  134. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–923.

    PubMed  CAS  Google Scholar 

  135. Lin CH, Lin SH, Jang FL. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J Clin Psychopharmacol. 2011;31:563–8.

    PubMed  Google Scholar 

  136. Lingjaerde O. Tetrabenazine in the treatment of psychoses. Acta Psychiatr Scand. 1963;39 (Suppl 17):1–109.

    PubMed  Google Scholar 

  137. Lipinski Jr JF, Zubenko GS, Cohen BM, Barreira PJ. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry. 1984;141:412–5.

    PubMed  Google Scholar 

  138. Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. Pharmacopsychiatry. 2004;37:134–8.

    PubMed  Google Scholar 

  139. Maheux J, Vuillier L, Mahfouz M, Rouillard C, Lévesque D. Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain. Int J Neuropsychopharmacol. 2012;15:509–21.

    Google Scholar 

  140. Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. J Clin Psychiatry. 2011;72:936–41.

    PubMed  Google Scholar 

  141. Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Safety. 2010;19:429–35.

    Google Scholar 

  142. Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl). 2007;191:805–11.

    CAS  Google Scholar 

  143. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600–10.

    PubMed  Google Scholar 

  144. McIntyre RS, Yoon J, Jerrell JM, Liauw SS. Aripiprazole for the maintenance treatment of bipolar disorder: review of available evidence. Neuropsychiatr Dis Treat. 2011;7:319–23.

    PubMed  CAS  Google Scholar 

  145. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91.

    PubMed  CAS  Google Scholar 

  146. Meltzer HY, Massey BW. Role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11:59–67.

    PubMed  CAS  Google Scholar 

  147. Merro DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005;25:32–41.

    Google Scholar 

  148. Mishara AL, Goldberg TE. Meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia. Biol Psychiatry. 2004;55:1013–22.

    PubMed  CAS  Google Scholar 

  149. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:10–28.

    PubMed  Google Scholar 

  150. Mizuno T, Schmauss C, Rayport S. Distinct roles of presynaptic dopamine receptors in the differential modulation of the intrinsic synapses of medium-spiny neurons in the nucleus accumbens. BMC Neurosci. 2007;8:8.

    PubMed  Google Scholar 

  151. Moghaddam B, Bunney BS. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse. 1993;14:195–200.

    PubMed  CAS  Google Scholar 

  152. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006;58:871–85.

    PubMed  CAS  Google Scholar 

  153. Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E. What we know and what we don’t know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol. 2011;21:680–90.

    PubMed  CAS  Google Scholar 

  154. Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, et al. Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;31:218–24.

    PubMed  CAS  Google Scholar 

  155. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23:649–59.

    PubMed  Google Scholar 

  156. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25:473–90.

    PubMed  CAS  Google Scholar 

  157. Nooijen PM, Carvalho F, Flanagan RJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol. 2011;26:112–9.

    PubMed  CAS  Google Scholar 

  158. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30:531–40.

    PubMed  Google Scholar 

  159. Nunn R. Mere anecdote: evidence and stories in medicine. J Eval Clin Pract. 2011;17:920–6.

    PubMed  Google Scholar 

  160. Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy: PET study in haloperidol-treated patients. Psychiatry Res. 1996;67:163–71.

    PubMed  CAS  Google Scholar 

  161. Ohaeri JU, Akanji AO. Metabolic syndrome in severe mental disorders. Metab Syndr Relat Disord. 2011;9:91–8.

    PubMed  Google Scholar 

  162. Parkinson CN. Parkinson’s law. The Economist, 19 November 1955.

    Google Scholar 

  163. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, et al. Weight effects associated with antipsychotics: comprehensive database analysis. Schizophr Res. 2009;110:103–10.

    PubMed  Google Scholar 

  164. Perenyi A, Gardos G, Samu I, Kallos M, Cole JO. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal. Clin Neuropharmacol. 1983;6:55–61.

    PubMed  CAS  Google Scholar 

  165. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010;12:CD000088.

    Google Scholar 

  166. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191–208.

    PubMed  CAS  Google Scholar 

  167. Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377–82.

    PubMed  CAS  Google Scholar 

  168. Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: pilot study. Biol Psychiatry. 1996;40:1132–4.

    PubMed  CAS  Google Scholar 

  169. Racoosin JA, Katz R. Overview of the effect of the WBC monitoring schedule on the rate of clozxapine-associated agranulocytosis: FDA memorandum 3950B1_02_A of May 19. 2003. http://www.fda.gov/ohrms/dockets/ac/03.

  170. Rado JT. Review of trials of mirtazapine for negative symptoms of schizophrenia. Psychiatr Ann. 2011;41:265–70.

    Google Scholar 

  171. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225–35.

    PubMed  CAS  Google Scholar 

  172. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161–7.

    PubMed  CAS  Google Scholar 

  173. Reiter S, Adler L, Angrist B, Corwin J, Rotrosen J. Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol. 1987;7:279–80.

    PubMed  CAS  Google Scholar 

  174. Reulbach U, Dütsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11:R4.

    PubMed  Google Scholar 

  175. Rosen SL, Baldessarini RJ. Costs of psychotropic drugs. 2011 (unpublished MS).

    Google Scholar 

  176. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89:1277–96.

    PubMed  CAS  Google Scholar 

  177. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. Clin Orthop Relat Res. 2007;455:3–5.

    PubMed  Google Scholar 

  178. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs. 2011;25:803–13.

    PubMed  CAS  Google Scholar 

  179. Schatzberg AF, Nemeroff CB, editors. The American psychiatric press textbook of psychopharmacology, 4th edn. Washington, DC: American Psychiatric Press; 2009.

    Google Scholar 

  180. Schlittler E, MacPhillamy HB, Dorfman L, Furlenmeier A, Huebner CF, Lucas R, et al. Chemistry of Rauwolfia alkaloids, including reserpine. Ann N Y Acad Sci. 1954;59:1–7.

    PubMed  CAS  Google Scholar 

  181. Schneider SD, Jelinek L, Lincoln TM, Moritz S. What happened to the voices? A fine-grained analysis of how hallucinations and delusions change under psychiatric treatment. Psychiatry Res. 2011;188:13–7.

    PubMed  Google Scholar 

  182. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010;4:56–73.

    PubMed  Google Scholar 

  183. Segnitz N, Ferbert T, Schmitt A, Gass P, Gebicke-Haerter PJ, Zink M. Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology (Berl). 2011;217:127–42.

    CAS  Google Scholar 

  184. Sen G, Bose KC. Rauwolfia serpentina, a new Indian drug for insanity and high blood pressure. Ind Med World. 1931;2:194–201.

    Google Scholar 

  185. Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17:417–27.

    PubMed  Google Scholar 

  186. Simpson GM, Yadalam KG, Levinson DF, Stephanos MJ, Lo ES, Cooper TB. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol. 1990;10:417–21.

    PubMed  CAS  Google Scholar 

  187. Singer HS. Treatment of tics and Tourette syndrome. Curr Treat Options Neurol. 2010;12:539–61.

    PubMed  Google Scholar 

  188. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37:1368–73.

    PubMed  CAS  Google Scholar 

  189. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;16:CD000209.

    Google Scholar 

  190. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006;5:25–43.

    PubMed  CAS  Google Scholar 

  191. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd ed. Edinburgh: Churchill-Livingstone; 2005.

    Google Scholar 

  192. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611–22.

    PubMed  Google Scholar 

  193. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001;72:325–36.

    PubMed  CAS  Google Scholar 

  194. Swazey JP. Chlorpromazine in psychiatry: a study in therapeutic innovation. Cambridge, MA: MIT; 1974.

    Google Scholar 

  195. Sylte I, Dahl SG. Molecular structure and dynamics of cis (Z)-and trans (E)-flupenthixol and clopenthixol. Pharm Res. 1991;8:462–70.

    PubMed  CAS  Google Scholar 

  196. Tarazi FI, Baldessarini RJ. Brain dopamine D4 receptors: basic and clinical status. Intl J Neuropsychopharmacol. 1999;2:41–58.

    CAS  Google Scholar 

  197. Tarazi FI, Baldessarini RJ. The dopamine D4 receptor: significance for molecular psychiatry at the millennium. Mol Psychiatry. 2000;4:529–38.

    Google Scholar 

  198. Tarazi FI, Baldessarini RJ. Comparative postnatal development of dopamine D1, D2 and D4 receptors in rat forebrain. Int J Dev Neurosci. 2000;18:29–37.

    PubMed  CAS  Google Scholar 

  199. Tarsy D, Baldessarini RJ. Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology. 1974;13:927–40.

    PubMed  CAS  Google Scholar 

  200. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–98.

    PubMed  Google Scholar 

  201. Tarsy D, Baldessarini RJ, Tarazi FI. Atypical antipsychotic agents: effects on extrapyramidal functions. CNS Drugs. 2002;16:23–45.

    PubMed  CAS  Google Scholar 

  202. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2010;100:601–16.

    Google Scholar 

  203. Terevnikov V, Stenberg JH, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol. 2011;26:188–93.

    PubMed  CAS  Google Scholar 

  204. Thuillier J. The Ten Years that Changed the Face of Mental Illness (Healy D, transl.). London: Martin Dunitz; 1999.

    Google Scholar 

  205. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. Nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–9.

    PubMed  Google Scholar 

  206. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620–7.

    PubMed  Google Scholar 

  207. Tiihonen J, Wahlbeck K, Kiviniemi V. Efficacy of lamotrigine in clozapine-resistant schizophrenia: systematic review and meta-analysis. Schizophr Res. 2009;109:10–4.

    PubMed  Google Scholar 

  208. Tohen M, Zarate Jr CA, Hennen J, Khalsa HMK, Strakowski SM, Gebre-Medhin P, et al. McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099–107.

    PubMed  Google Scholar 

  209. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy. 1994;14:543–60.

    PubMed  CAS  Google Scholar 

  210. Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010;64:79–87.

    PubMed  CAS  Google Scholar 

  211. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.

    PubMed  CAS  Google Scholar 

  212. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318–25.

    PubMed  CAS  Google Scholar 

  213. Undurraga J, Baldessarini RJ. A 30-year meta-analytic review of antidepressant efficacy in acute major depression. Neuropsychopharmacology. 2012;37:851–64.

    PubMed  CAS  Google Scholar 

  214. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1704–8.

    PubMed  Google Scholar 

  215. Vázquez G, Baldessarini RJ, Yildiz A, Tamayo J, Tondo L, Salvatore P. Multi-site international collaborative clinical trials in mania: commentary. Int J Neuropsychopharmacol. 2011;14:1013–6.

    PubMed  Google Scholar 

  216. Velligan DI, Alphs LD. Negative symptoms in schizophrenia: importance of identification and treatment. Psychiatr Times. 2008;25:1–2. http://www.psychiatrictimes.com/schizophrenia/content/article/10168/1147581?.

  217. Velligan DI, Gonzalez JM. Rehabilitation and recovery in schizophrenia. Psychiatr Clin North Am. 2007;30:535–48.

    PubMed  Google Scholar 

  218. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Srinivas Bharath MM, Shankar SK. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Neurochem Res. 2012;37:358–69.

    PubMed  CAS  Google Scholar 

  219. Ventriglio A, Vincenti A, Centorrino F, Talamo A, Fitzmaurice G, Baldessarini RJ. Use of mood-stabilizers for hospitalized adult psychotic and bipolar disorder patients. Int Clin Psychopharmacol. 2011;26:88–95.

    PubMed  Google Scholar 

  220. Vetti HH, Molven A, Eliassen AK, Steen VM. Is pharmacogenetic CYP2D6 testing useful? Tidsskr Nor Laegeforen. 2010;130:2224–8.

    PubMed  Google Scholar 

  221. Viguera AC, Baldessarini RJ, Hegarty JM, Van Kammen D, Tohen M. Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry. 1997;54:49–55.

    PubMed  CAS  Google Scholar 

  222. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990–9.

    PubMed  CAS  Google Scholar 

  223. Waldorf S. Neuroleptic malignant syndrome. Am Assoc Nurse Anesth J. 2003;71:389–94.

    Google Scholar 

  224. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–41.

    PubMed  CAS  Google Scholar 

  225. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002;59:1147–54.

    PubMed  CAS  Google Scholar 

  226. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011;68:899–904.

    PubMed  Google Scholar 

  227. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21:25–35.

    PubMed  CAS  Google Scholar 

  228. Wiesel FA, Farde L, Nordström AL, Sedvall G. Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14: 759–67.

    PubMed  CAS  Google Scholar 

  229. Winkleman Jr NW. Chlorpromazine in the treatment of neuropsychiatric disorders. JAMA. 1954;155:18–21.

    Google Scholar 

  230. Williams JM, Galli A. The dopamine transporter: a vigilant border control for psychostimulant action. Handb Exp Pharmacol. 2006;175:215–32.

    PubMed  CAS  Google Scholar 

  231. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry. 2001;62 (Suppl 21):15–8.

    PubMed  CAS  Google Scholar 

  232. Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology. 2011;36:1738–46.

    PubMed  CAS  Google Scholar 

  233. Wong DF. In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research. Arch Gen Psychiatry. 2002;59:31–4.

    PubMed  CAS  Google Scholar 

  234. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011;6:CD002831.

    Google Scholar 

  235. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375–89.

    PubMed  CAS  Google Scholar 

  236. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011;14:863–75.

    PubMed  CAS  Google Scholar 

  237. Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: review from a clinical perspective. World J Biol Psychiatry. 2012;13:96–105.

    PubMed  Google Scholar 

  238. Zink M, Englisch S, Meyer-Lindenberg A. [Polypharmacy in schizophrenia]. Nervenarzt. 2011;82:853–88.

    PubMed  CAS  Google Scholar 

  239. Zyss T, Banach M, Zieba A. [Akathisia—diagnosis, pathophysiology and therapy (Polish)]. Psychiatr Pol. 2009;43:387–402.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, McLean Hospital Psychopharmacology Program, Belmont, MA, USA

    Ross J. Baldessarini

Authors
  1. Ross J. Baldessarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Baldessarini, R.J. (2013). Antipsychotic Agents. In: Chemotherapy in Psychiatry. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3710-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3710-9_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7926-0

  • Online ISBN: 978-1-4614-3710-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation